Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Updated results from CARTITUDE-1

Yi Lin • 11 Jun 2022
EHA 2022
Multiple Myeloma CAR-T Ciltacabtagene autoleucel
CARTITUDE-1

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some updated results from a 27-month follow-up of the CARTITUDE-1 trial (NCT03548207), investigating the use of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory (R/R) myeloma, drawing focus on the impressive response rates observed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Yi Lin

Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5 1:41
Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5
Yi Lin • 4 Sep 2025
Real-world evidence on the outcomes of CD19 CAR T-cell therapy in aggressive lymphoma 2:02
Real-world evidence on the outcomes of CD19 CAR T-cell therapy in aggressive lymphoma
Yi Lin • 4 Sep 2025
Guidance for junior researchers entering the cellular therapy field 1:55
Guidance for junior researchers entering the cellular therapy field
Yi Lin • 4 Sep 2025
The transformative effect of immunotherapies on the treatment landscape of DLBCL 3:06
The transformative effect of immunotherapies on the treatment landscape of DLBCL
Yi Lin • 4 Sep 2025

Related Videos

Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis 2:35
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Alexander Lesokhin • 8 Dec 2025
Integrated approaches to improve prognosis prediction in multiple myeloma 2:32
Integrated approaches to improve prognosis prediction in multiple myeloma
Claudio Cerchione • 6 Dec 2025
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals